1. Home
  2. NUVL
  3. NUVL News

Latest Nuvalent Inc. (NUVL) News on October 30, 2025

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
NUVL

PR Newswire

12 days ago

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

NUVL

MT Newswires

12 days ago

Nuvalent Insider Sold Shares Worth $1,279,018, According to a Recent SEC Filing

NUVL

MT Newswires

12 days ago

Nuvalent Insider Sold Shares Worth $2,540,290, According to a Recent SEC Filing

NUVL

MT Newswires

12 days ago

Nuvalent Insider Sold Shares Worth $2,447,021, According to a Recent SEC Filing

NUVL

MT Newswires

a month ago

Nuvalent Insider Sold Shares Worth $2,346,256, According to a Recent SEC Filing

NUVL

MT Newswires

2 months ago

Nuvalent Insider Sold Shares Worth $293,642, According to a Recent SEC Filing

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
NUVL

PR Newswire

2 months ago

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Nuvalent price target raised to $140 from $125 at Leerink
NUVL

TipRanks

4 months ago

Nuvalent price target raised to $140 from $125 at Leerink

Nuvalent price target raised to $130 from $110 at H.C. Wainwright
NUVL

TipRanks

4 months ago

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

NUVL

MT Newswires

4 months ago

Nuvalent Reports Positive Data From Phase 1/2 Trial of Zidesamtinib in Lung Cancer

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
NUVL

PR Newswire

4 months ago

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug
NUVL

BioPharma Dive

4 months ago

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
NUVL

PR Newswire

4 months ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Nuvalent Appoints Christy Oliger to Board of Directors
NUVL

PR Newswire

4 months ago

Nuvalent Appoints Christy Oliger to Board of Directors

NUVL

MT Newswires

4 months ago

Nuvalent Insider Sold Shares Worth $2,077,093, According to a Recent SEC Filing

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
NUVL

PR Newswire

6 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
NUVL

PR Newswire

6 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying
NUVL

Insider Monkey

6 months ago

Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying

Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
NUVL

Insider Monkey

6 months ago

Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
NUVL

PR Newswire

6 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?
NUVL

Insider Monkey

7 months ago

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
NUVL

PR Newswire

7 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy
NUVL

Insider Monkey

7 months ago

Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
NUVL

PR Newswire

7 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

NUVL

MT Newswires

7 months ago

Nuvalent Insider Sold Shares Worth $2,048,562, According to a Recent SEC Filing

NUVL

MT Newswires

8 months ago

UBS Upgrades Nuvalent to Buy From Neutral, Maintains $100 Price Target

NUVL

MT Newswires

8 months ago

Nuvalent Insider Sold Shares Worth $2,443,578, According to a Recent SEC Filing

Nuvalent to Participate in Upcoming March Investor Conferences
NUVL

PR Newswire

8 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

NUVL

MT Newswires

8 months ago

Nuvalent's Q4 Net Loss Widens

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results
NUVL

PR Newswire

8 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently
NUVL

Insider Monkey

9 months ago

Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently

Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans
NUVL

Simply Wall St.

9 months ago

Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans

Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
NUVL

Insider Monkey

9 months ago

Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
NUVL

PR Newswire

10 months ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

NUVL

MT Newswires

10 months ago

Nuvalent Insider Sold Shares Worth $320,009, According to a Recent SEC Filing

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls
NUVL

The Fly

10 months ago

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

NUVL

MT Newswires

10 months ago

HC Wainwright Initiates Nuvalent at Buy With $110 Price Target

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NUVL

PR Newswire

10 months ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NUVL

MT Newswires

10 months ago

Nuvalent Insider Sold Shares Worth $2,338,436, According to a Recent SEC Filing

Nuvalent Appoints Grant Bogle to Board of Directors
NUVL

PR Newswire

a year ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
NUVL

PR Newswire

a year ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

NUVL

MT Newswires

a year ago

Nuvalent's Q3 Net Loss Widens

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
NUVL

PR Newswire

a year ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $442,980, According to a Recent SEC Filing

NUVL

MT Newswires

a year ago

UBS Initiates Nuvalent With Neutral Rating, $100 Price Target

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $508,718, According to a Recent SEC Filing

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
NUVL

Zacks

a year ago

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $3,244,140, According to a Recent SEC Filing

NUVL

MT Newswires

a year ago

Nuvalent Raises $575 Million From Share Offering

Nuvalent Announces Closing of Upsized Public Offering of Common Stock
NUVL

PR Newswire

a year ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL

Zacks

a year ago

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

Company News for Sep 17, 2024
NUVL

Zacks

a year ago

Company News for Sep 17, 2024

NUVL

MT Newswires

a year ago

Nuvalent Prices $500 Million Stock Offering

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
NUVL

PR Newswire

a year ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
NUVL

Investor's Business Daily

a year ago

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

NUVL

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

NUVL

MT Newswires

a year ago

Top Midday Gainers

NUVL

MT Newswires

a year ago

Update: Nuvalent Shares Jump After Trials of Lung Cancer Drugs Show 'Favorable Tolerability'

Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
NUVL

Barrons.com

a year ago

Cancer Biotech Nuvalent’s Stock Jumps on Positive Data

NUVL

MT Newswires

a year ago

Nuvalent Says 2 Potential Lung Cancer Drugs Show 'Favorable Tolerability'

NUVL

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

NUVL

MT Newswires

a year ago

Sector Update: Health Care

NUVL

MT Newswires

a year ago

Nuvalent Launches $350 Million Common Stock Offering

NUVL

MT Newswires

a year ago

Wedbush Raises Price Target on Nuvalent to $115 From $99, Keeps Outperform Rating

Nuvalent Announces Public Offering of Common Stock
NUVL

PR Newswire

a year ago

Nuvalent Announces Public Offering of Common Stock

Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
NUVL

Insider Monkey

a year ago

Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks

Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
NUVL

Insider Monkey

a year ago

Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
NUVL

PR Newswire

a year ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
NUVL

PR Newswire

a year ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
NUVL

PR Newswire

a year ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
NUVL

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
NUVL

PR Newswire

a year ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

NUVL

MT Newswires

a year ago

Barclays Initiates Nuvalent at Overweight

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $935,440, According to a Recent SEC Filing

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $893,340, According to a Recent SEC Filing

NUVL

MT Newswires

a year ago

Nuvalent's Q2 Net Loss Widens

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
NUVL

PR Newswire

a year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $795,074, According to a Recent SEC Filing

Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment
NUVL

Clinical Trials Arena

a year ago

Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
NUVL

PR Newswire

a year ago

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
NUVL

PR Newswire

a year ago

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

NUVL

MT Newswires

a year ago

Nuvalent Names Henry Pelish Chief Scientific Officer; Shares Rise

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
NUVL

PR Newswire

a year ago

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

NUVL

MT Newswires

a year ago

Stifel Adjusts Price Target on Nuvalent to $115 From $103, Maintains Buy Rating

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $643,213, According to a Recent SEC Filing

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
NUVL

PR Newswire

a year ago

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing

FDA grants breakthrough therapy status for Nuvalent’s NVL-655
NUVL

Pharmaceutical Technology

a year ago

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

NUVL

MT Newswires

a year ago

Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL

PR Newswire

a year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

NUVL

MT Newswires

a year ago

Nuvalent Q1 Net Loss Widens

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL

PR Newswire

a year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing

Why Earnings Season Could Be Great for Nuvalent (NUVL)
NUVL

Zacks

a year ago

Why Earnings Season Could Be Great for Nuvalent (NUVL)

NUVL

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL

PR Newswire

2 years ago

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
NUVL

GuruFocus.com

2 years ago

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
NUVL

Barrons.com

2 years ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
NUVL

GuruFocus.com

2 years ago

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)

Share on Social Networks: